Core Viewpoint - The stock of Haishike experienced a decline of 2.03% on September 15, 2023, with a current price of 56.90 CNY per share and a total market capitalization of 63.723 billion CNY, despite a year-to-date increase of 72.53% [1] Financial Performance - For the first half of 2025, Haishike reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2] - Cumulative cash dividends since the A-share listing amount to 3.673 billion CNY, with 687 million CNY distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400, with an average of 42,147 circulating shares per shareholder, down by 28.64% [2] - The top ten circulating shareholders include several funds, with notable increases in holdings by China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [3]

Core Viewpoint - As of September 15, 2023, Aosaikang's stock price has shown significant volatility, with a year-to-date increase of 76.65% but a recent decline in the last 20 days by 15.41% [1] Financial Performance - For the first half of 2025, Aosaikang reported a revenue of 1.007 billion yuan, representing a year-on-year growth of 9.20%, and a net profit attributable to shareholders of 160 million yuan, which is a substantial increase of 111.64% [2] - Cumulative cash dividends since Aosaikang's A-share listing amount to 721 million yuan, with 111 million yuan distributed over the past three years [3] Shareholder Structure - As of August 20, 2023, Aosaikang had 18,300 shareholders, a decrease of 1.26% from the previous period, with an average of 50,724 circulating shares per shareholder, an increase of 1.28% [2] - Notable changes in institutional holdings include new entries such as Yongying Pharmaceutical Innovation Mixed Fund and Hong Kong Central Clearing Limited, while some funds like China Europe Medical Health Mixed Fund have exited the top ten shareholders list [3] Market Activity - On September 15, 2023, Aosaikang's stock experienced a decline of 2.03%, trading at 22.24 yuan per share, with a total market capitalization of 20.642 billion yuan [1] - The stock has seen a net inflow of 3.5584 million yuan from major funds, with significant buying activity accounting for 11.74% of total transactions [1]

Core Viewpoint - The stock of Haishike has shown significant performance with a year-to-date increase of 76.74%, despite a recent decline over the past 20 days [1][2]. Group 1: Stock Performance - As of September 11, Haishike's stock price reached 58.29 CNY per share, with a market capitalization of 65.28 billion CNY [1]. - The stock has experienced a 1.78% increase over the last five trading days and a 37.93% increase over the last 60 days [1]. - The company has seen a net outflow of 4.30 million CNY in principal funds, with large orders showing a buy of 14.74 million CNY and a sell of 19.74 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Haishike reported a revenue of 2.00 billion CNY, reflecting an 18.63% year-on-year growth, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2]. - Cumulatively, the company has distributed 3.67 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400, with an average of 42,147 circulating shares per person, down by 28.64% [2]. - The top ten circulating shareholders include several mutual funds, with notable increases in holdings from institutions such as China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [3].

Company Overview - Haisco Pharmaceutical Group Co., Ltd. is located in Zedang Town, Shannan City, Tibet, and was established on August 26, 2005. The company was listed on January 17, 2012. Its main business involves the research, development, production, and sales of chemical pharmaceuticals. The revenue composition is 99.14% from the pharmaceutical industry and 0.86% from other sources [1]. Stock Performance - As of September 5, Haisco's stock price decreased by 2.04%, trading at 56.10 CNY per share, with a total market capitalization of 62.827 billion CNY. The stock has increased by 70.10% year-to-date, with a 1.15% increase over the last five trading days, a 5.65% decrease over the last 20 days, and a 20.78% increase over the last 60 days [1]. Financial Performance - For the first half of 2025, Haisco reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%. However, the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2]. Shareholder Information - As of June 30, 2025, Haisco had 11,400 shareholders, an increase of 25.93% from the previous period. The average number of tradable shares per shareholder decreased by 28.64% to 42,147 shares [2]. Dividend Distribution - Haisco has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, several funds increased their holdings, including China Europe Medical Health Mixed A, which holds 21.2763 million shares, an increase of 5.3574 million shares. Other funds also saw increases, while one fund reduced its holdings [3].

Core Viewpoint - As of September 4, 2023, Aosaikang's stock price has shown significant volatility, with a year-to-date increase of 82.29% but a recent decline in the last five and twenty trading days [1] Financial Performance - For the first half of 2025, Aosaikang reported a revenue of 1.007 billion yuan, representing a year-on-year growth of 9.20%, and a net profit attributable to shareholders of 160 million yuan, which is a substantial increase of 111.64% [2] - Cumulative cash dividends since Aosaikang's A-share listing amount to 721 million yuan, with 111 million yuan distributed over the past three years [3] Shareholder Structure - As of August 20, 2025, Aosaikang has 18,300 shareholders, a decrease of 1.26% from the previous period, with an average of 50,724 circulating shares per shareholder, an increase of 1.28% [2] - The top ten circulating shareholders include new entrants such as Yongying Pharmaceutical Innovation Mixed Fund and Hong Kong Central Clearing Limited, while some existing shareholders like E Fund Medical Health Mixed Fund have reduced their holdings [3] Market Activity - Aosaikang's stock experienced a trading volume of 1.04 billion yuan on September 4, 2023, with a turnover rate of 0.48% and a total market capitalization of 21.301 billion yuan [1] - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 16 [1]

Core Viewpoint - The stock of Zhongsheng Pharmaceutical has experienced fluctuations, with a year-to-date increase of 72.05%, but a recent decline of 3.56% over the last five trading days [1] Financial Performance - For the first half of 2025, Zhongsheng Pharmaceutical reported revenue of 1.3 billion yuan, a year-on-year decrease of 4.74%, while net profit attributable to shareholders increased by 114.96% to 188 million yuan [2] - The company has distributed a total of 2.019 billion yuan in dividends since its A-share listing, with 502 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Zhongsheng Pharmaceutical was 89,900, a decrease of 1.32% from the previous period, with an average of 8,470 circulating shares per shareholder, an increase of 1.33% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 9.1731 million shares, a new addition, while other significant shareholders have reduced their holdings [3] Market Activity - On September 3, 2023, Zhongsheng Pharmaceutical's stock price was 20.56 yuan per share, with a trading volume of 2.32 billion yuan and a turnover rate of 1.46% [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent net purchase of 181 million yuan on July 29 [1] Business Overview - Zhongsheng Pharmaceutical, established on December 31, 2001, and listed on December 11, 2009, is primarily engaged in the research, production, and sales of pharmaceuticals, with 96.13% of its revenue coming from pharmaceutical manufacturing [1]

Company Overview - Angli康 is a pharmaceutical company based in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company specializes in the research, production, and sales of chemical raw materials and formulations [1]. - The main business revenue composition includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Stock Performance - As of September 1, Angli康's stock price increased by 2.00% to 50.41 CNY per share, with a trading volume of 215 million CNY and a turnover rate of 2.34%, resulting in a total market capitalization of 10.169 billion CNY [1]. - Year-to-date, Angli康's stock price has risen by 286.05%, but it has seen a decline of 9.37% over the last five trading days and 22.09% over the last 20 days. In the last 60 days, the stock price increased by 134.92% [1]. Financial Performance - For the first half of 2025, Angli康 reported a revenue of 724 million CNY, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.925 million CNY, down 3.19% year-on-year [2]. - Since its A-share listing, Angli康 has distributed a total of 341 million CNY in dividends, with 108 million CNY distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, Angli康 had 18,500 shareholders, an increase of 50.49% from the previous period. The average number of circulating shares per person decreased by 33.55% to 10,037 shares [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.4373 million shares, and Guangfa Technology Innovation Mixed A, holding 6.1606 million shares [3].

Core Viewpoint - Guotou Zhonglu reported significant growth in revenue and net profit for the first half of 2025, indicating strong operational performance in the juice production and processing industry [1][2]. Financial Performance - The company's revenue for the first half of 2025 was 1.007 billion yuan, a year-on-year increase of 39.68% [1]. - The net profit attributable to shareholders was 25.08 million yuan, up 2149.03% year-on-year [1]. - The basic earnings per share were 0.10 yuan, with a weighted average return on equity of 2.73% [1]. - The gross margin for the first half was 14.62%, a decrease of 1.13 percentage points year-on-year, while the net margin was 3.71%, an increase of 3.03 percentage points [1]. Quarterly Insights - In Q2 2025, the gross margin was 13.26%, showing a year-on-year increase of 0.16 percentage points but a quarter-on-quarter decrease of 2.40 percentage points [1]. - The net margin for Q2 was 0.38%, up 2.21 percentage points year-on-year but down 5.85 percentage points from the previous quarter [1]. Expense Analysis - Total operating expenses for the first half were 103 million yuan, an increase of 10.59 million yuan year-on-year, with an expense ratio of 10.27%, down 2.61 percentage points [2]. - Sales expenses increased by 15.18%, while management expenses decreased by 0.78%, and R&D expenses saw a significant reduction of 45.69% [2]. - Financial expenses rose by 51.13% [2]. Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 13,100, an increase of 1,309 or 11.07% from the previous quarter [2]. - The average market value held per shareholder dropped from 281,200 yuan to 0 yuan, indicating a 100% decline [2]. Company Overview - Guotou Zhonglu is located in Beijing and was established on September 18, 1991, with its listing date on June 22, 2004 [2]. - The company primarily engages in the production, processing, and export of concentrated juice, with juice, spices, and fructose accounting for 99.01% of its main business revenue [2]. - The company belongs to the agricultural and forestry industry, specifically in the agricultural product processing sector, focusing on fruit and vegetable processing [2].

Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. is located at 1000 North Shengzhou Avenue, Shengzhou City, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company's main business involves the research, production, and sales of chemical raw materials and formulations [1][2]. Financial Performance - As of March 31, 2025, Anglikang reported a revenue of 346 million yuan, a year-on-year decrease of 15.31%, and a net profit attributable to shareholders of 15.91 million yuan, down 43.63% year-on-year [2]. - The company has cumulatively distributed 341 million yuan in dividends since its A-share listing, with 108 million yuan distributed over the past three years [3]. Stock Performance - On August 27, Anglikang's stock price fell by 2.04% to 51.80 yuan per share, with a trading volume of 303 million yuan and a turnover rate of 3.11%, resulting in a total market capitalization of 10.45 billion yuan [1]. - Year-to-date, Anglikang's stock price has increased by 296.69%, with a 4.75% rise over the last five trading days, a 0.38% decline over the last 20 days, and a 209.85% increase over the last 60 days [1]. Shareholder Information - As of March 31, 2025, Anglikang had 12,300 shareholders, an increase of 10.23% from the previous period, with an average of 15,104 circulating shares per shareholder, a decrease of 9.28% [2]. - Among the top ten circulating shareholders, Xinyi Medical Care A (011466) ranked as the eighth largest, holding 1.1006 million shares, a decrease of 288,300 shares from the previous period [3]. Industry Classification - Anglikang belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and chemical formulation sectors. The company is associated with concepts such as ursodeoxycholic acid, hypertension treatment, Helicobacter pylori concepts, synthetic biology, and innovative drugs [2].

Company Overview - Aosaikang Pharmaceutical Co., Ltd. is located in Jiangning Science Park, Nanjing, Jiangsu Province, and was established on December 24, 1996. The company was listed on May 15, 2015. Its main business involves the research, production, and sales of drugs, particularly in the fields of digestive, anti-tumor, and other medications [1][2]. Financial Performance - For the first quarter of 2025 (January to March), Aosaikang achieved a revenue of 509 million yuan, representing a year-on-year growth of 13.39%. The net profit attributable to shareholders was 54.73 million yuan, showing a significant increase of 73.50% compared to the previous year [2]. - Since its A-share listing, Aosaikang has distributed a total of 721 million yuan in dividends, with 111 million yuan distributed over the past three years [3]. Stock Performance - As of August 26, Aosaikang's stock price was 25.01 yuan per share, with a market capitalization of 23.213 billion yuan. The stock has increased by 98.65% year-to-date, but has seen a decline of 1.96% over the past five trading days and a 10.36% drop over the past 20 days [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 16 [1]. Shareholder Information - As of August 20, Aosaikang had 18,300 shareholders, a decrease of 1.26% from the previous period. The average number of circulating shares per shareholder increased by 1.28% to 50,724 shares [2]. - Among the top ten circulating shareholders as of March 31, 2025, notable new entrants include China Europe Medical Health Mixed A and E Fund Medical Health Industry Mixed A, while Hong Kong Central Clearing Limited has exited the list [3]. Industry Classification - Aosaikang is classified under the pharmaceutical and biological industry, specifically in the chemical pharmaceutical sector, with a focus on innovative drugs, pharmaceutical e-commerce, and cancer treatment [2].